These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 25945734)
1. Erbb4 Signaling: an overlooked backup system? Ni Y; Zhang S Cell Cycle; 2015; 14(11):1623. PubMed ID: 25945734 [No Abstract] [Full Text] [Related]
2. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells. Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338 [TBL] [Abstract][Full Text] [Related]
3. Prognostic value of ERBB family mRNA expression in breast carcinomas. Bièche I; Onody P; Tozlu S; Driouch K; Vidaud M; Lidereau R Int J Cancer; 2003 Sep; 106(5):758-65. PubMed ID: 12866037 [TBL] [Abstract][Full Text] [Related]
5. Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis. Fujiwara S; Ibusuki M; Yamamoto S; Yamamoto Y; Iwase H Breast Cancer; 2014 Jul; 21(4):472-81. PubMed ID: 23100016 [TBL] [Abstract][Full Text] [Related]
7. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855 [TBL] [Abstract][Full Text] [Related]
8. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer. Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079 [TBL] [Abstract][Full Text] [Related]
9. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells. Kim J; Lee J; Kim C; Choi J; Kim A Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908 [TBL] [Abstract][Full Text] [Related]
10. MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance. Paulson AK; Linklater ES; Berghuis BD; App CA; Oostendorp LD; Paulson JE; Pettinga JE; Melnik MK; Vande Woude GF; Graveel CR Mol Cancer Res; 2013 Sep; 11(9):1112-21. PubMed ID: 23825050 [TBL] [Abstract][Full Text] [Related]
12. The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors. Slamon DJ Oncologist; 2004; 9 Suppl 3():1-3. PubMed ID: 15163840 [No Abstract] [Full Text] [Related]
13. [Relation between c-erbB1, c-erbB2, MAPK expression and resistance to tamoxifen in breast cancer cells in vitro]. Zhang QY; Zhao WH; Kang XM Zhonghua Zhong Liu Za Zhi; 2006 Nov; 28(11):826-30. PubMed ID: 17416003 [TBL] [Abstract][Full Text] [Related]
14. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946 [TBL] [Abstract][Full Text] [Related]
15. ERBB4 promotes the proliferation of gastric cancer cells via the PI3K/Akt signaling pathway. Xu J; Gong L; Qian Z; Song G; Liu J Oncol Rep; 2018 Jun; 39(6):2892-2898. PubMed ID: 29620274 [TBL] [Abstract][Full Text] [Related]
16. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu. Piechocki MP; Yoo GH; Dibbley SK; Lonardo F Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894 [TBL] [Abstract][Full Text] [Related]
17. ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy. Elizalde PV; Cordo Russo RI; Chervo MF; Schillaci R Endocr Relat Cancer; 2016 Dec; 23(12):T243-T257. PubMed ID: 27765799 [TBL] [Abstract][Full Text] [Related]
18. Treatment for the endocrine resistant breast cancer: Current options and future perspectives. Liu CY; Wu CY; Petrossian K; Huang TT; Tseng LM; Chen S J Steroid Biochem Mol Biol; 2017 Sep; 172():166-175. PubMed ID: 28684381 [TBL] [Abstract][Full Text] [Related]
19. The role of ErbB inhibitors in trastuzumab resistance. Miller KD Oncologist; 2004; 9 Suppl 3():16-9. PubMed ID: 15163843 [TBL] [Abstract][Full Text] [Related]
20. Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells. Lammering G; Lin PS; Contessa JN; Hampton JL; Valerie K; Schmidt-Ullrich RK Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):775-84. PubMed ID: 11697324 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]